ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.
Identifieur interne : 001B51 ( Ncbi/Merge ); précédent : 001B50; suivant : 001B52ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.
Auteurs : Hooman Ganjavi [Canada] ; Penny A. MacdonaldSource :
- The Journal of neuropsychiatry and clinical neurosciences [ 1545-7222 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antipsychotic Agents, Dopamine Agents.
- complications : Parkinson Disease.
- drug therapy : Psychotic Disorders.
- etiology : Psychotic Disorders.
- Aged, Analysis of Variance, Case-Control Studies, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales.
Abstract
Psychiatric manifestations of Parkinson's disease (PD) are a cause of significant disability and the impact of dopaminergic medications is unclear. Using standardized rating scales, the authors tested the hypothesis that anxiety, depression, and apathy vary in the ON versus OFF states in PD in 33 PD patients and 29 healthy age- and education-matched controls. PD patients had significantly higher anxiety, depression, and apathy scores than control participants, regardless of ON-OFF state. Anxiety scores were higher in PD patients on relative to off dopaminergic medication. The ON-OFF difference in anxiety related to degree of improvement in motor function but not illness duration.
DOI: 10.1176/appi.neuropsych.14030055
PubMed: 25923857
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000601
- to stream PubMed, to step Curation: 000601
- to stream PubMed, to step Checkpoint: 000601
Links to Exploration step
pubmed:25923857Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.</title><author><name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name><affiliation wicri:level="1"><nlm:affiliation>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada (PAM).</nlm:affiliation><country>Canada</country><wicri:regionArea>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A" last="Macdonald">Penny A. Macdonald</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25923857</idno><idno type="pmid">25923857</idno><idno type="doi">10.1176/appi.neuropsych.14030055</idno><idno type="wicri:Area/PubMed/Corpus">000601</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000601</idno><idno type="wicri:Area/PubMed/Curation">000601</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000601</idno><idno type="wicri:Area/PubMed/Checkpoint">000601</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000601</idno><idno type="wicri:Area/Ncbi/Merge">001B51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.</title><author><name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name><affiliation wicri:level="1"><nlm:affiliation>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada (PAM).</nlm:affiliation><country>Canada</country><wicri:regionArea>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A" last="Macdonald">Penny A. Macdonald</name></author></analytic><series><title level="j">The Journal of neuropsychiatry and clinical neurosciences</title><idno type="eISSN">1545-7222</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Antipsychotic Agents (therapeutic use)</term><term>Case-Control Studies</term><term>Dopamine Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Psychiatric Status Rating Scales</term><term>Psychotic Disorders (drug therapy)</term><term>Psychotic Disorders (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Psychiatric Status Rating Scales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Psychiatric manifestations of Parkinson's disease (PD) are a cause of significant disability and the impact of dopaminergic medications is unclear. Using standardized rating scales, the authors tested the hypothesis that anxiety, depression, and apathy vary in the ON versus OFF states in PD in 33 PD patients and 29 healthy age- and education-matched controls. PD patients had significantly higher anxiety, depression, and apathy scores than control participants, regardless of ON-OFF state. Anxiety scores were higher in PD patients on relative to off dopaminergic medication. The ON-OFF difference in anxiety related to degree of improvement in motor function but not illness duration.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25923857</PMID><DateCreated><Year>2015</Year><Month>04</Month><Day>30</Day></DateCreated><DateCompleted><Year>2016</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.</ArticleTitle><Pagination><MedlinePgn>e134-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.14030055</ELocationID><Abstract><AbstractText>Psychiatric manifestations of Parkinson's disease (PD) are a cause of significant disability and the impact of dopaminergic medications is unclear. Using standardized rating scales, the authors tested the hypothesis that anxiety, depression, and apathy vary in the ON versus OFF states in PD in 33 PD patients and 29 healthy age- and education-matched controls. PD patients had significantly higher anxiety, depression, and apathy scores than control participants, regardless of ON-OFF state. Anxiety scores were higher in PD patients on relative to off dopaminergic medication. The ON-OFF difference in anxiety related to degree of improvement in motor function but not illness duration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ganjavi</LastName><ForeName>Hooman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Dept. of Psychiatry, University of Western Ontario, London, Ontario, Canada (HG); The Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada (PAM); and Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada (PAM).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Penny A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25923857</ArticleId><ArticleId IdType="doi">10.1176/appi.neuropsych.14030055</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Macdonald, Penny A" sort="Macdonald, Penny A" uniqKey="Macdonald P" first="Penny A" last="Macdonald">Penny A. Macdonald</name></noCountry><country name="Canada"><noRegion><name sortKey="Ganjavi, Hooman" sort="Ganjavi, Hooman" uniqKey="Ganjavi H" first="Hooman" last="Ganjavi">Hooman Ganjavi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001B51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25923857
|texte= ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson's Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25923857" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |